PMSF

• Description :

  PMSF (Phenylmethylsulfonyl fluoride) is a nonspecific and irreversible serine proteases inhibitor. PMSF inhibits some thiol proteases, non-protease enzymes, and acetylcholinesterase. PMSF can be used to prepare protein extracts from tissue and cell lysates[1][2][3][4].

• Product Name Alternative :

  Phenylmethylsulfonyl fluoride; Benzylsulfonyl fluoride

• UNSPSC :

  12352005

• Hazard Statement :

  H225, H315, H319

• Target :

  Cathepsin; Ser/Thr Protease

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/pmsf.html

• Purity :

  99.49

• Solubility :

  DMSO : 250 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL|Isopropyl alcohol : 60 mg/mL (ultrasonic)

• Smiles :

  O=S(CC1=CC=CC=C1)(F)=O

• Molecular Formula :

  C7H7FO2S

• Molecular Weight :

  174.19

• Precautions :

  H225, H315, H319

• References & Citations :

  [1]Sekar, M.C. and B.D. Roufogalis, Differential effects of phenylmethanesulfonyl fluoride (PMSF) on carbachol and potassium stimulated phosphoinositide turnover and contraction in longitudinal smooth muscle of guinea pig ileum. Cell Calcium, 1984. 5 (3) : p.|[2]Guther, M.L., W.J. Masterson, and M.A. Ferguson, The effects of phenylmethylsulfonyl fluoride on inositol-acylation and fatty acid remodeling in African trypanosomes. J Biol Chem, 1994. 269 (28) : p. 18694-701.|[3]Compton, D.R. and B.R. Martin, The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther, 1997. 283 (3) : p. 1138-43.|[4]Asadi Akbarabadi E, et a. PMSF Attenuates Morphine Antinociceptive Tolerance and Dependence in Mice: Its Association with the Oxidative Stress Suppression. Iran J Pharm Res. 2021 Summer;20 (3) :300-309.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [329-98-6]